微芯生物(688321.SH)与Nizhpharm签署西达本胺许可及分销协议

Group 1 - The company Microchip Biotech (688321.SH) has signed a licensing and distribution agreement with Nizhny Novgorod Chemical Pharmaceutical Plant (Nizhpharm) for its product Chidamide [1][2] - Nizhpharm will obtain exclusive rights for the research, registration, and commercialization of Chidamide in several countries including Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Mongolia, Russia, Tajikistan, Uzbekistan, Georgia, and Turkmenistan [1][2] - The agreement includes an upfront payment of 10 million RMB and additional milestone payments totaling 10 million RMB for local registration [2] Group 2 - Nizhpharm is one of the leading pharmaceutical companies in the Russian Federation, focusing on unmet medical needs and has a modern production base compliant with GMP standards [2] - Chidamide is the world's first subtype-selective histone deacetylase (HDAC) inhibitor, marking a significant milestone for Chinese innovative drugs in licensing to Europe and the United States [2] - Nizhpharm will be solely responsible for the product's research, registration, secondary packaging, transportation, and commercialization in the authorized regions [2]